ELISA results demonstrated that the levels of TGF‐β1, IL‐10, IL‐23, and IL‐17 were significantly higher in CRC patients (Figure 4A, 15.67 ± 5.22 for HC and 27.91 ± 8.75 for CRC, p < .001; 4B 23.18 ± 7.19 for HC and 39.42 ± 10.79 for CRC, p < .001; 4 C 38.15 ± 15.27 for HC and 45.27 ± 11.41 for CRC, p = .001; 4D 19.59 ± 9.71 for HC and 24.32 ± 8.03 for CRC, p < .001). Here, TGFB1 is linked to colorectal carcinoma.